Ocular Safety and Toxicology of Subretinal Gene Therapy With rAAV.hPDE6A in Nonhuman Primates
Translational Vision Science & Technology · 29.01.2025 · 14 (1) · 29
DOI: 10.1167/tvst.14.1.29 ↗Kurz gefasst
Fachartikel in der Zeitschrift Translational Vision Science & Technology, erschienen am 29.01.2025. Verfasst von Immanuel P Seitz und 11 weiteren Autor:innen. Beteiligte Einrichtung: University Eye Hospital Tuebingen, Centre for Ophthalmology, University of Tuebingen, Tuebingen, Germany. Hauptthemen laut MEDLINE: Genetic Therapy, Dependovirus, Genetic Vectors, Retina. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
Reports of gene therapy-associated retinal atrophies and inflammation have highlighted the importance of preclinical safety assessments of adeno-associated virus (AAV) vector systems. We evaluated in nonhuman primates (NHPs) the ocular safety and toxicology of a novel AAV gene therapy targeting retinitis pigmentosa caused by mutations in PDE6A, which has since been used in a phase I/II clinical trial (NCT04611503).
Methods
A total of 34 healthy cynomolgus animals (Macaca fascicularis) were treated with subretinal injections of rAAV.hPDE6A and followed over 13 weeks. Three dose levels (low: 1 × 1011, intermediate: 5 × 1011, and high: 1 × 1012 vector genomes [vg]) were compared to sham-injected controls. Safety and toxicity were determined using ophthalmic examinations, electroretinography, ocular histology, and retinal imaging.
Results
At the low and intermediate doses, inflammation was mild, electroretinography response was unimpeded, and histology results were in line with surgically induced changes. In contrast, three high-dose animals displayed atrophic changes of the retina and abnormalities in electroretinography, which were considered test article related and adverse.
Conclusions
A single subretinal injection of up to 5 × 1011 vg was well tolerated, and a 10-fold lower dose of 5 × 1010 vg was chosen as the starting dose for the ongoing phase I/II clinical trial. Atrophic retinal changes and abnormalities in electroretinography emerged as dose-limiting findings in the high-dose cohort. Translational Relevance: This study demonstrates that treatment candidate rAAV.PDE6A was well tolerated in NHPs. Occurrence of retinal atrophy as a dose-limiting finding highlights the importance of further study into the mechanisms of atrophy induction after retinal gene therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- University Eye Hospital Tuebingen, Centre for Ophthalmology, University of Tuebingen, Tuebingen, Germany.
- University Eye Hospital Munich, Munich, Germany.
- Labcorp Early Development Services GmbH, Muenster, Germany.
- Virscio, Inc., New Haven, CT, USA.
- STZ eyetrial at the Centre for Ophthalmology, Tuebingen, Germany.
- Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
Zitieren
APA
Seitz, I. P., Wozar, F., Ochakovski, G. A., Reichel, F. F., Korte, S., Korbmacher, B., Wilhelm, B., Süsskind, D., Bartz-Schmidt, K. U., Fischer, M. D., Peters, T., & RD Cure Consortium (2025). Ocular Safety and Toxicology of Subretinal Gene Therapy With rAAV.hPDE6A in Nonhuman Primates. Translational Vision Science & Technology, 14(1), 29. https://doi.org/10.1167/tvst.14.1.29
Vancouver
Seitz IP, Wozar F, Ochakovski GA, Reichel FF, Korte S, Korbmacher B, et al. Ocular Safety and Toxicology of Subretinal Gene Therapy With rAAV.hPDE6A in Nonhuman Primates. Translational Vision Science & Technology. 2025;14(1):29. doi:10.1167/tvst.14.1.29
BibTeX
@article{Seitz2025,
author = {Seitz, Immanuel P and Wozar, Fabian and Ochakovski, Guy Alex and Reichel, Felix F and Korte, Sven and Korbmacher, Birgit and Wilhelm, Barbara and Süsskind, Daniela and Bartz-Schmidt, Karl-Ulrich and Fischer, M Dominik and Peters, Tobias and RD Cure Consortium, RD Cure Consortium},
title = {Ocular Safety and Toxicology of Subretinal Gene Therapy With rAAV.hPDE6A in Nonhuman Primates},
journal = {Translational Vision Science & Technology},
year = {2025},
volume = {14},
number = {1},
pages = {29},
doi = {10.1167/tvst.14.1.29}
}
EUVIMED